Publications by authors named "J I Mechanick"
A 40-year-old woman at 35 weeks of gestation presented with abdominal pain and hypertriglyceridemia of above 5000 mg/dL. Following lab tests and imaging studies, she was diagnosed with hypertriglyceridemia-related acute pancreatitis in pregnancy. She was managed with NPO, IV insulin, and peripheral parenteral nutrition, but her condition further complicated with preeclampsia, and she was induced and delivered at 36 weeks of gestation.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines how ethno-racial disparities in cardiometabolic diseases are influenced by socioeconomic, behavioral, and environmental factors, using a Bayesian network approach based on 20 years of data.
- - It identifies several pathways linking ethno-racial group to cardiometabolic outcomes, highlighting that education and behavioral factors like diet and physical activity play varying roles among different groups.
- - The findings indicate that while improved diet and activity lower disease risk more for non-Hispanic Whites, these factors are less effective for non-Hispanic Blacks and Hispanics, suggesting the need to explore unmeasured structural determinants affecting health disparities in these communities.
Background: Digital twin (DT)-guided lifestyle changes induce type 2 diabetes (T2D) remission but effects on hypertension (HTN) in this population are unknown.
Objectives: The purpose of this study was to assess effects of DT vs standard of care (SC) on blood pressure (BP), anti-HTN medication, HTN remission, and microalbuminuria in participants with T2D.
Methods: This is a secondary analysis of a randomized controlled trial in India of 319 participants with T2D.
As adiposity increases in youth, so does the prevalence of cardiometabolic risk factors (CMRFs). The etiology of adiposity-based chronic disease and CMRFs includes ethnoracial disparities that are rarely considered in current treatment approaches. Precision interventions require further characterization of these disparities among high-risk youth.
View Article and Find Full Text PDFThe rapid and widespread clinical adoption of highly effective incretin-mimetic drugs (IMDs), particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the updating of clinical practice guidelines. Consequently, many patients may be at risk for adverse effects and uncertain long-term outcomes related to the use of these drugs. Of emerging concern is the loss of skeletal muscle mass and function that can accompany rapid substantial weight reduction; such losses can lead to reduced functional and metabolic health, weight cycling, compromised quality of life, and other adverse outcomes.
View Article and Find Full Text PDF